Norwegian University Of Science And Technolology
- Address
- Hoegskoleringen 1, 7034 Trondheim, Norway
Norwegian University of Science and Technology - Clinical Research
The Norwegian University of Science and Technology conducts advanced clinical research across multiple therapeutic areas, with particular emphasis on neurological disorders and metabolic diseases. Their research portfolio demonstrates a commitment to investigating innovative treatment approaches and long-term patient outcomes in complex medical conditions.
- Neurodegenerative disease research focusing on early symptomatic phase Alzheimer's disease
- Autoimmune diabetes studies including Latent Autoimmune Diabetes in Adults (LADA) with novel immunotherapy interventions
- Advanced interventional pain management research for chronic cluster headache using image-guided techniques
The institution's research initiatives span from evaluating the safety and feasibility of emerging therapies in Alzheimer's disease to long-term follow-up studies assessing beta cell function in diabetes patients treated with GAD-alum immunotherapy. Their work in headache disorders includes pioneering interventions targeting the sphenopalatine ganglion using sophisticated surgical guidance systems for refractory chronic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Norwegian University Of Science And Technolology
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Botulinum Toxin Type A in Sphenopalatine Ganglion Blockade for Refractory Chronic Cluster Headache Treatment | Norwegian University Of Science And Technolology | Phase III | Recruiting | Nov 2019 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A | 1 | Unknown | 2019-11-01 | 2019-11-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.